You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Dr. Cristian Rodriguez-Aguayo (University of Texas MD Anderson Cancer Center, Houston, TX), who was awarded the Non-Coding RNA Travel Award, attended the Targeted Anticancer Therapies (TAT) 2018 meeting held in Paris (France) between 5th and 7th March.
The Targeted Anticancer Therapies (TAT) congress is considered one of the most prominent congresses in the field and a premier forum for the discussion of early phase drug development and translational research. The congress provides an important venue for discussions shaping the most promising paths for the development of new therapeutics and offers an opportunity to shape future of drug development together with the world’s most renowned experts.
Dr. Cristian Rodriguez-Aguayo’s research focuses on the understanding of the functional basis and biological mechanisms in which RBPs and non-coding RNAs promote cancer growth and tumor progression. At this meeting, Dr. Rodriguez-Aguayo showed his findings in a poster presentation entitled “Regulation of hnRNPA1 by microRNAs controls the miR-18a–KRAS axis in chemotherapy-resistant ovarian cancer”.